<![CDATA[Radiation Omission in Favorable Breast Cancer Hinges on Endocrine Adherence]]>

Data ReadoutNeutral

AI Analysis

Summary

Leah Katz, MD, MPH, discusses long-term data from the IDEA trial on omitting radiation in favorable-risk breast cancer. She highlights that tolerance of and adherence to endocrine therapy are central to this decision.

Clinical Trial Data

Outcome Details

Long-term data from the IDEA trial on omitting radiation in favorable breast cancer; expert commentary emphasizes endocrine therapy tolerance and adherence as key to the decision.

Importance:3/10

Sentiment:

0.20

breast cancerradiation omissionendocrine therapyIDEA trialexpert commentaryoncology

Read the original article

Published by Cancer Network on October 17, 2026 4:00 PM

Read Original